Who
Stephen Michael Kelsey
Officer
Company insider
Files Form 4 as: Officer, Revolution Medicines; SVP of New Projects, Medivation; EVP, R&D, Chief Med Officer, Geron.
In numbers
- Trades disclosed
- 196
- Buys
- 0
- Sells
- 61
- Bought
- $0
- Sold
- $61.4M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 20 May 2009
- Last trade
- 16 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $17K85 at $195.01 | filing |
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $1.1M5,484 at $199.30 | filing |
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $17K85 at $195.01 | filing |
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $1.1M5,484 at $199.30 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $2.2M52,500 at $42.45 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $673K3,270 at $205.81 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | $2.2M52,500 at $42.45 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | $1.6M40,031 at $40.74 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $1.6M40,031 at $40.74 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $159K800 at $198.55 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | $2.2M52,500 at $42.45 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | $1.6M40,031 at $40.74 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $2.4M11,833 at $200.11 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $2.7M13,368 at $200.78 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $4.3M21,447 at $201.75 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $3.8M18,869 at $203.06 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $3.7M17,949 at $203.87 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $1.0M4,995 at $204.84 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $2.2M52,500 at $42.45 | filing |
| 11 Sep 2026filed 15 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $1.6M40,031 at $40.74 | filing |
News
Stephen Michael Kelsey Sells 5,569 Shares of Revolution Medicines (NASDAQ:RVMD) Stocktickerreport.com · 18 Sep 2026Revolution Medicines' Pancreatic Cancer Drug Gets Positive EU ReviewRVMD · finanzen.ch · 15 Oct 2026Revolution Medicines (NASDAQ:RVMD) Shares Up 3.4% on Analyst UpgradeRVMD · themarketsdaily.com · 14 Oct 2026Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' DaraxonrasibRVMD · manilatimes.net · 7 Oct 2026
1 headline in the last 90 days name Stephen Michael Kelsey; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.